Defendant Name:
Teva Pharmaceutical Industries Limited
Defendant Type:
Public Company
Document Reference:
LR-23708
Document Details
Legal Case Name
SEC v. Teva Pharmaceutical Industries Ltd.
Document Name
SEC Charges Israel-Based Pharmaceutical Company with FCPA Violations
Document Date
22-Dec-2016
Document Format
Civil Proceeding
Case Number
16-cv-25298
Federal District Court
Florida, Southern District of Florida
Allegation Type
Foreign Corrupt Practices Act
Document Summary
On December 22, 2016, the SEC announced in a litigation release that Teva has agreed to settle parallel civil and criminal charges in relation to its violations of the FCPA. According to the SEC: "Teva made more than $214 million in illicit profits by making the influential payments to increase its market share and obtain regulatory and formulary approvals as well as favorable drug purchase and prescription decisions."
Disgorgement & Penalty Information
Resolutions
Enjoinment
Compliance Related Independent Consultant